UY36199A - Compuesto heterocíclico - Google Patents

Compuesto heterocíclico

Info

Publication number
UY36199A
UY36199A UY0001036199A UY36199A UY36199A UY 36199 A UY36199 A UY 36199A UY 0001036199 A UY0001036199 A UY 0001036199A UY 36199 A UY36199 A UY 36199A UY 36199 A UY36199 A UY 36199A
Authority
UY
Uruguay
Prior art keywords
heterocyclic compound
present
rqryt
symbol
salts
Prior art date
Application number
UY0001036199A
Other languages
English (en)
Inventor
Yamamoto Satoshi
Shirai Junya
Oda Tsuneo
Tokuhara Hidekazu
Tomata Yoshihide
Ishii Naoki
Tawada Michiko
Ochida Atsuko
Imada Takashi
Fukase Yoshiyuki
Yukawa Tomoya
Kono Mitsunori
Fukumoto Shoji
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of UY36199A publication Critical patent/UY36199A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

La presente invención proporciona un compuesto heterocíclico con una acción inhibidora de RQRyt. La presente invención se refiere a un compuesto representado por la fórmula (I): en donde cada símbolo es como se define en la memoria descriptiva, o una de sus sales.
UY0001036199A 2014-07-01 2015-07-01 Compuesto heterocíclico UY36199A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2014136359 2014-07-01
JP2014262775 2014-12-25

Publications (1)

Publication Number Publication Date
UY36199A true UY36199A (es) 2016-01-29

Family

ID=53724416

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036199A UY36199A (es) 2014-07-01 2015-07-01 Compuesto heterocíclico

Country Status (23)

Country Link
US (5) US9365520B2 (es)
EP (1) EP3164388A1 (es)
JP (1) JP6611363B2 (es)
KR (1) KR20170016987A (es)
CN (1) CN106795118B (es)
AU (1) AU2015285142B2 (es)
CA (1) CA2954042A1 (es)
CL (1) CL2016003326A1 (es)
CO (1) CO2017000332A2 (es)
CR (1) CR20170017A (es)
DO (1) DOP2016000337A (es)
EA (1) EA031262B1 (es)
GE (1) GEP20196942B (es)
IL (1) IL249698A0 (es)
MA (1) MA40060A (es)
MX (1) MX2016016870A (es)
PE (1) PE20170267A1 (es)
PH (1) PH12016502574A1 (es)
SG (1) SG11201610729XA (es)
TN (1) TN2016000567A1 (es)
TW (1) TW201609751A (es)
UY (1) UY36199A (es)
WO (1) WO2016002968A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015002231A1 (ja) * 2013-07-03 2015-01-08 武田薬品工業株式会社 複素環化合物
CR20170017A (es) * 2014-07-01 2017-05-16 Takeda Pharmaceuticals Co Compuesto heterocíclico
JPWO2016039408A1 (ja) 2014-09-11 2017-06-22 武田薬品工業株式会社 複素環化合物
CN105472125B (zh) * 2015-11-16 2019-11-26 联想(北京)有限公司 一种信息处理方法及电子设备
AU2016374294B2 (en) 2015-12-15 2019-06-27 Astrazeneca Ab Isoindole compounds
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
WO2017197055A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
EP3638661A1 (en) 2017-06-14 2020-04-22 Astrazeneca AB 2,3-dihydroisoindole-1-carboxamides useful as ror-gamma modulators
WO2019044940A1 (ja) * 2017-08-31 2019-03-07 東レ株式会社 環状アミン誘導体及びその医薬用途
EP3651747A4 (en) 2017-11-17 2020-07-22 Cellix Bio Private Limited COMPOSITIONS AND METHODS OF TREATMENT OF EYE DISORDERS
RU2020123538A (ru) * 2018-01-31 2022-03-03 Торэй Индастриз, Инк. Производное циклического амина и его медицинское применение
RU2686692C1 (ru) * 2018-06-29 2019-04-30 Федеральное Государственное Бюджетное Учреждение Науки Институт Биохимической Физики Им. Н.М. Эмануэля Российской Академии Наук (Ибхф Ран) Применение N-(6,8,8-триметил-8,9-дигидрофуро[3,2-h]хинолин-5-ил)ацетамида в качестве средства для фототерапии псориаза и псориатического артрита
WO2020132561A1 (en) 2018-12-20 2020-06-25 C4 Therapeutics, Inc. Targeted protein degradation
US20230192620A1 (en) * 2020-05-15 2023-06-22 Shanghai Litedd Co., Ltd. ANILINE COMPOUND USED AS RORy REGULATOR
EP4213775A1 (en) 2020-09-21 2023-07-26 Ocon Medical Ltd Device positionable in the uterine cavity and method of treatment thereof
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7250415B2 (en) 2003-06-04 2007-07-31 Bristol-Myers Squibb Company 1,1-Disubstitutedcycloalkyl-, glycinamidyl-, sulfonyl-amidino-, and tetrahydropyrimidinyl-containing diaminoalkyl, β-aminoacids, α-aminoacids and derivatives thereof as factor Xa inhibitors
WO2008121602A1 (en) 2007-03-29 2008-10-09 Smithkline Beecham Corporation Chemical compounds
FR2945535B1 (fr) 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant
WO2013018695A1 (ja) 2011-07-29 2013-02-07 武田薬品工業株式会社 複素環化合物
WO2013042782A1 (ja) * 2011-09-22 2013-03-28 武田薬品工業株式会社 縮合複素環化合物
WO2013055984A1 (en) 2011-10-14 2013-04-18 Bristol-Myers Squibb Company Substituted tetrahydroisoquinoline compounds as factor xia inhibitors
CN103987696B (zh) * 2011-10-14 2016-12-21 百时美施贵宝公司 作为因子xia抑制剂的取代的四氢异喹啉化合物
WO2013100027A1 (ja) * 2011-12-28 2013-07-04 武田薬品工業株式会社 複素環化合物
US9403774B2 (en) * 2012-10-12 2016-08-02 Bristol-Myers Squibb Company Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors
EP2975031A4 (en) 2013-03-14 2017-04-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
JP6411342B2 (ja) 2013-07-03 2018-10-24 武田薬品工業株式会社 アミド化合物
WO2015002231A1 (ja) * 2013-07-03 2015-01-08 武田薬品工業株式会社 複素環化合物
CR20170017A (es) 2014-07-01 2017-05-16 Takeda Pharmaceuticals Co Compuesto heterocíclico

Also Published As

Publication number Publication date
TW201609751A (zh) 2016-03-16
CO2017000332A2 (es) 2017-07-11
JP2017527530A (ja) 2017-09-21
CL2016003326A1 (es) 2017-08-11
GEP20196942B (en) 2019-02-11
US9365520B2 (en) 2016-06-14
CA2954042A1 (en) 2016-01-07
US9630924B2 (en) 2017-04-25
US20170144973A1 (en) 2017-05-25
WO2016002968A1 (en) 2016-01-07
JP6611363B2 (ja) 2019-11-27
AU2015285142B2 (en) 2019-02-21
CR20170017A (es) 2017-05-16
EP3164388A1 (en) 2017-05-10
PH12016502574A1 (en) 2017-04-17
MA40060A (fr) 2016-01-07
PE20170267A1 (es) 2017-04-12
US9650343B2 (en) 2017-05-16
EA201790112A1 (ru) 2017-05-31
TN2016000567A1 (en) 2018-04-04
US9573903B2 (en) 2017-02-21
AU2015285142A1 (en) 2017-02-02
SG11201610729XA (en) 2017-01-27
US20160176872A1 (en) 2016-06-23
KR20170016987A (ko) 2017-02-14
MX2016016870A (es) 2017-05-01
US20160176873A1 (en) 2016-06-23
US10093629B2 (en) 2018-10-09
EA031262B1 (ru) 2018-12-28
US20160002169A1 (en) 2016-01-07
US20160176822A1 (en) 2016-06-23
CN106795118A (zh) 2017-05-31
CN106795118B (zh) 2019-10-08
IL249698A0 (en) 2017-02-28
DOP2016000337A (es) 2017-04-16

Similar Documents

Publication Publication Date Title
UY36199A (es) Compuesto heterocíclico
TR201905829T4 (tr) Buzdolabı.
DOP2016000206A (es) Compuesto heterocíclico fusionado
UY35821A (es) Compuesto heterocíclico
UY36315A (es) COMPUESTOS NOVEDOSOS ANTAGONISTAS DE INTEGRINA avß6.
TR201906366T4 (tr) Polisiklik-karbamoilpiridon bileşiklerinin sentezi.
CR20160368A (es) Compuesto heterocíclico
CR20160459A (es) Nuevos derivados de piridina
DK3552017T3 (da) Forbindelser, der er anvendelige som ripk1-inhibitorer
MX2016003892A (es) Uso de dihidrooxindolilsulfonamidas sustituidas, o sus sales, para aumentar la tolerancia de plantas al estres.
CR20160448A (es) Nuevos derivados de piridina
EA201692028A1 (ru) Применение замещенных оксотетрагидрохинолинилсульфонамидов или их солей для повышения стрессоустойчивости растений
BR112016028022A2 (pt) compostos de sulfonamida e seus usos como inibidores de stat5
ECSP13012535A (es) Compuesto heterocíclico y sus usos
EA201691999A1 (ru) Новые сульфониламинобензамидные соединения
BR112016027455A2 (pt) moduladores ppar
EA201892449A1 (ru) Конденсированные гетероциклические соединения
MX2017010901A (es) Colorantes de acido trisazo.
DK3138840T3 (da) Thiadiazolidin-derivat som anti-enterovirus 71
UY35714A (es) ?arroz resistente a herbicidas inhibidores de hppd y accasa?.
BR112019002828A2 (pt) método de preparação de derivados de estireno substituído
EA201790238A1 (ru) Кристаллические ингибиторы bace
BR112015028751A2 (pt) processo para a preparação de derivados de 3,5-bis (fluoralquil)pirazol a partir de alfa,alfa-dihaloaminas
UY36363A (es) Compuesto heterocíclico fusionado
UA108340U (uk) Морфолінію 1-н-бутилтеобромін-8-ілтіоацетат, який виявляє діуретичну дію

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20220705